Webinar: The Faster Path to Self-Administration – Moving from Pre-Filled Syringe to Auto-Injector
Date: October 15, 2020
Time: 10:00 am ET
As a pharma company looks to make the transition from a traditional pre-filled syringe (PFS) to an auto-injector, both its device partner and its manufacturing partner must bring their own set of expertise to the 3-way partnership. It’s imperative that the three teams work together to meet product, device, quality, manufacturing, and packaging requirements. When experienced partners understand lifecycle management and anticipate equipment and process needs, the product can be transitioned from PFS to auto-injector more quickly.
In this webinar, we will share:
- How product characteristics and formulation determine the type of auto-injector best suited for your product
- How the chosen auto-injector affects manufacturing and packaging of the finished product
- What quality considerations are necessary as a product transitions to auto-injector
- How the above coupled with integrated PFS manufacturing and auto-injector assembly can create an accelerated timeline to market
Business Development Director, Ypsomed Delivery Systems
Orfeo Niedermann’s responsibilities at Ypsomed include business development activities in the US, Europe, Japan and China as well as product strategy for Ypsomed’s range of YpsoMate autoinjector devices. He has spoken at numerous international
conferences and authored or co-authored a number of articles.
Orfeo Niedermann has studied mechanical engineering at the Swiss Federal Institute of Technology in Zurich, Switzerland (MSc ETH) and management in Bern (MBA BFH).
Sr. Manager, Manufacturing Technology, Catalent Biologics
Pam Barton is Senior Manager, Manufacturing Technology for Catalent Biologics and has over 15 years of experience in the pharmaceutical industry and biologics space. Pam is responsible for the primary and secondary packaging technical teams at Catalent Biologics’ facility in Bloomington, Indiana. Prior to Catalent, Pam was a Pharmaceutical Scientist for Cook Pharmica, a company acquired by Catalent, and spent over eight years at Boehringer Ingelheim in formulations and validation. Pam holds a B.S. in Biological Engineering from the University of Guelph.